Remarkable advances have been made over past decades in understanding the
pathogenesis of complement-mediated diseases. This has led to development of new
therapies for, and in some cases re-classification of, complement-driven diseases. This
success is due to not only insight from human patients but also studies using transgenic
animal models. Animal models that mimic human diseases are useful tools to understand
the mechanism of disease and develop new therapies but there are also limitations due to …